The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDiaceutics Regulatory News (DXRX)

Share Price Information for Diaceutics (DXRX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 102.50
Bid: 101.00
Ask: 104.00
Change: 4.50 (4.59%)
Spread: 3.00 (2.97%)
Open: 97.00
High: 102.50
Low: 97.00
Prev. Close: 98.00
DXRX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Significant upgrade to Diaceutics' DXRX platform

21 Mar 2024 07:00

RNS Number : 6750H
Diaceutics PLC
21 March 2024
 

Reach

Diaceutics launches significant upgrade to its DXRX platform

New functionality will involve a best in class combination of generative AI and integrated data solutions to improve patient outcomes

Belfast and London, 21 March 2024 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, has launched a significant upgrade to its DXRX platform, including industry and technologically leading de-identification, generative AI (Diaceutics Large Lab Model, DLLM) and new comprehensive US data sets that include data on social determinants of health. Not only does the upgrade increase the power and efficiency of the platform, but also the applicability of Diaceutics' subscription services into new parts of the precision medicine lifecycle, expanding the Company's addressable market.

This new functionality enables the DXRX platform to breakdown siloed datasets and provide greater depth and breadth of Diaceutics' longitudinal insight of the patient journey, at increased speed and scale. As a result of the upgrade, multiple stakeholders within the life sciences industry can now access a best in class, real world data set that is HIPAA compliant, at a pace that previously would not have been possible, helping to address healthcare inequalities and enable more patients to access appropriate therapies.

Jordan Clark, Chief Data Officer of Diaceutics commented: "Our Practise Gaps Study identified that a staggering 64.4% of patients do not get the right treatment. We seek to address that through the insights we provide, and today's platform upgrade will empower healthcare providers to make timely and accurate treatment decisions, ultimately benefiting more patients."

Enquiries: 

 

Diaceutics PLC?

Ryan Keeling, Chief Executive Officer  

Nick Roberts, Chief Financial Officer 

Jordan Clark, Chief Data Officer 

 

Tel: +44 (0)28 9040 6500

investorrelations@diaceutics.com

 

Stifel Nicolaus Europe Limited (Nomad & Broker) 

Tel: +44 (0)20 7710 7600 

Ben Maddison 

Nick Harland 

Kate Hanshaw

Alma Strategic Communications

Tel: +44(0)20 3405 0205 

Caroline Forde

Kinvara Verdon

Kieran Breheny 

diaceutics@almastrategic.com

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome.

 

We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network ®.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAQKKBKOBKDCNB
Date   Source Headline
7th Sep 20202:00 pmRNSPrice Monitoring Extension
7th Sep 202011:00 amRNSPrice Monitoring Extension
7th Sep 20207:00 amRNSHalf-year Report
27th Aug 20207:00 amRNSNotice of Results
22nd Jul 20207:00 amRNSNew contract win for DXRX platform
9th Jul 20207:00 amRNSHolding(s) in Company
8th Jul 20207:00 amRNSTrading update
6th Jul 20204:41 pmRNSSecond Price Monitoring Extn
6th Jul 20204:36 pmRNSPrice Monitoring Extension
3rd Jul 202010:43 amRNSHolding(s) in Company
3rd Jul 20207:00 amRNSIssue of Share Options
29th Jun 20202:55 pmRNSResult of General Meeting
19th Jun 20207:00 amRNSHolding(s) in Company
11th Jun 20202:00 pmRNSExercise of warrant
11th Jun 20207:00 amRNSPlacing of £20.5 million
19th May 20202:29 pmRNSResult of AGM
19th May 20207:00 amRNSAGM Statement
18th May 20207:00 amRNSDiagnostic network for precision medicine update
5th May 202011:22 amRNSDirector’s Shareholding - PCA Dealing
29th Apr 20207:00 amRNSCancer testing & diagnosis suffers sharp downturn
23rd Apr 20207:00 amRNSPosting of Annual Report and Notice of AGM
6th Apr 20207:00 amRNSIssue of Share Options
19th Mar 20207:00 amRNSBelfast investor presentation
17th Mar 20209:05 amRNSSecond Price Monitoring Extn
17th Mar 20209:00 amRNSPrice Monitoring Extension
16th Mar 202011:05 amRNSSecond Price Monitoring Extn
16th Mar 202011:00 amRNSPrice Monitoring Extension
16th Mar 20207:00 amRNSFinal Results
12th Mar 20202:24 pmRNSPrivate investor briefing
27th Feb 20207:00 amRNSNotice of Results
17th Feb 20207:00 amRNSBelfast investor presentation
6th Feb 20207:00 amRNSGrowth & Innovation Forum 2020
17th Jan 20202:53 pmRNSHolding(s) in Company
13th Jan 20209:05 amRNSSecond Price Monitoring Extn
13th Jan 20209:00 amRNSPrice Monitoring Extension
13th Jan 20207:00 amRNSYear-End Trading Update
25th Nov 20197:00 amRNSPresentation at AICon 2019
24th Oct 20197:00 amRNSPresentation at Big Data Belfast
21st Oct 20197:00 amRNSPharma Precision Medicine Readiness Report
10th Oct 20197:00 amRNSWorkshop presentation at EORTC
30th Sep 20198:01 amRNSPoster presentation at ESMO
23rd Sep 20197:00 amRNSDublin investor presentation
9th Sep 20197:00 amRNSHalf-year Report
8th Aug 20197:00 amRNSAppointment of Head of Global Data
8th Aug 20197:00 amRNSNotice of Results
8th Jul 20197:00 amRNSTrading update
17th Jun 20197:00 amRNSInvestment in data lake
28th May 20197:00 amRNSInvestor presentation
25th Mar 20194:29 pmRNSHolding(s) in Company
25th Mar 20197:00 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.